一次情報の記録
決定級トップライン結果
Candel、aglatimagene besadenovecの前立腺がんにおけるPhase 3 DFSベネフィットを報告
無作為化Phase 3試験（n=745）の長期追跡データにより、aglatimagene besadenovec＋プロドラッグ＋標準治療放射線療法が、プラセボと比較して前立腺がん特異的無病生存期間を有意に改善したことが示された（HR 0.61, p=0.0031）。同社はまた、活性群において救済療法、生化学的失敗、および転移までの期間が延長したことを観察した。
主要事実
出典の抜粋
EX-99.1 2 d106447dex991.htm EX-99.1 EX-99.1 AUA Investor Call Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer May 15, 2026 NASDAQ: CADL Exhibit 99.1 Forward-looking statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Presentation, including express or implied statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market size, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “pla